Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | TDO2 | P48775 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218361 | 1.00 | NPC1 (0.62) | NPC1IDO1TDO2ALDH1A1KMT2A | |
| SCHEMBL3947925 | 0.88 | MEN1 (0.52) | NPC1IDO1TDO2ALDH1A1KMT2A | |
| SCHEMBL11339085 | 0.87 | HCRTR1 (0.58) | NPC1ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL447573 | 0.86 | NPC1 (0.70) | NPC1IDO1TDO2ALDH1A1KMT2A | |
| SCHEMBL3175398 | 0.86 | ABCB1 (0.48) | NPC1IDO1TDO2ALDH1A1KMT2A | |
| SCHEMBL2666954 | 0.86 | KDM4E (0.58) | NPC1IDO1TDO2ALDH1A1KMT2A | |
| SCHEMBL28280043 | 0.86 | TAS1R3 (0.53) | NPC1IDO1TDO2ALDH1A1KMT2A | |
| SCHEMBL4319748 | 0.86 | CTNNB1 (0.57) | NPC1IDO1TDO2ALDH1A1KMT2A | |
| SCHEMBL30038244 | 0.84 | CTSD (0.51) | NPC1IDO1TDO2ALDH1A1KMT2A | |
| SCHEMBL31039791 | 0.84 | NPC1 (0.59) | NPC1IDO1TDO2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105523874-A | Preparation method of 2,2-dihalo-1,3-dicarbonyl derivatives | ZHANGJIAGANG INST IND TECHNOLOGIES SOOCHOW UNIV | 2016-04-27 | — | — | CN | claimed |
| CN-105503635-A | Preparation method for 2-amidoformyl-1,3-dicarbonyl derivative | UNIV SOOCHOW | 2016-04-20 | — | — | CN | claimed |
| CN-105461496-A | Preparation method for 2-halogenated-1,3-dicarbonyl derivative | CHINASUN SPECIALTY PRODUCTS CO LTD | 2016-04-06 | — | — | CN | claimed |
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20240368106-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-117069720-A | 5-HT 2A Receptor agonist, preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-109942523-B | Benzofuran and benzofuran coumarin derivatives, and preparation method and application thereof | 华东师范大学 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023034340-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034339-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034346-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| CN-114057666-B | Synthesis method of 4, 5-disubstituted-2-aminothiazole compound | 沈阳药科大学 | 2023-02-07 | — | — | CN | disclosed |
| EP-0971921-A1 | 2-ARYL-NAPHTHYRIDIN-4-ONES AS ANTITUMOR AGENTS | The University of North Carolina at Chapel Hill (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5994367-A | PREVENT CELL MITOSIS; ANTICARCINOGENIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1998039332-A1 | 2-ARYL-NAPHTHYRIDIN-4-ONES AS ANTITUMOR AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-09-11 | — | — | WO | disclosed |
| EP-0203791-B1 | SPIRO-IMIDAZOLIDINES AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| EP-0142324-B1 | PHENYLALKANOIC ACID DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-01-04 | — | — | EP | disclosed |
| US-4668698-A | [(4-phenyl-1,3-dioxan-cis-5-yl)alkyl]phenylalkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-26 | — | — | US | disclosed |
| EP-0203791-A1 | Spiro-imidazolidines as aldose reductase inhibitors | PFIZER INC. (US) | 1986-12-03 | — | — | EP | disclosed |
| US-4575507-A | COMPLICATIONS OF DIABETES | PFIZER INC. (US) | 1986-03-11 | — | — | US | disclosed |
| EP-0142324-A2 | Phenylalkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | NPC1 1952/4885IDO1 2907/4885TDO2 2506/4885 |
| US-20240368106-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | POLRMT, ACAT1, TFAM | NPC1 700/4885IDO1 4576/4885TDO2 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.